Cargando…

circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment

Exonic circular RNAs (circRNAs) produce predominantly non-coding RNA species that have been recently profiled in many tumors. However, their functional contribution to cancer progression is still poorly understood. Here, we identify the circRNAs expressed in soft tissue sarcoma cells and explore how...

Descripción completa

Detalles Bibliográficos
Autores principales: Piras, Roberta, Ko, Emily Y., Barrett, Connor, De Simone, Marco, Lin, Xianzhi, Broz, Marina T., Tessaro, Fernando H. G., Castillo-Martin, Mireia, Cordon-Cardo, Carlos, Goodridge, Helen S., Di Vizio, Dolores, Batish, Mona, Lawrenson, Kate, Chen, Y. Grace, Chan, Keith Syson, Guarnerio, Jlenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700836/
https://www.ncbi.nlm.nih.gov/pubmed/36433954
http://dx.doi.org/10.1038/s41467-022-34872-8
Descripción
Sumario:Exonic circular RNAs (circRNAs) produce predominantly non-coding RNA species that have been recently profiled in many tumors. However, their functional contribution to cancer progression is still poorly understood. Here, we identify the circRNAs expressed in soft tissue sarcoma cells and explore how the circRNAs regulate sarcoma growth in vivo. We show that circCsnk1g3 and circAnkib1 promote tumor growth by shaping a pro-tumorigenic microenvironment, possibly due to their capabilities to regulate tumor-promoting elements extrinsic to the tumor cells. Accordingly, circCsnk1g3 and circAnkib1 can control the expression of interferon-related genes and pro-inflammatory factors in the sarcoma cells, thus directing immune cell recruitment into the tumor mass, and hence their activation. Mechanistically, circRNAs may repress pro-inflammatory elements by buffering activation of the pathways mediated by RIG-I, the cytosolic viral RNA sensor. The current findings suggest that the targeting of specific circRNAs could augment the efficacy of tumor and immune response to mainstay therapies.